Sihuan Pharmaceutical Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an announcement.

Sihuan Pharmaceutical Holdings Group Ltd. has announced that its board of directors will convene a meeting on 31 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the publication of these results and discuss the potential approval of a final dividend, a move that could signal the company’s confidence in its financial performance and provide guidance to shareholders on capital return expectations.

The planned board meeting underscores the company’s adherence to corporate governance norms for timely financial disclosure on the Hong Kong market. Any decision on a final dividend will be closely watched by investors as an indicator of earnings quality, cash generation, and management’s outlook, potentially influencing Sihuan Pharmaceutical’s valuation and its positioning among regional pharmaceutical peers.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd. is a Hong Kong‑listed pharmaceutical company incorporated in Bermuda and traded under stock code 0460. The group operates through multiple subsidiaries, focusing on the development, production, and sale of pharmaceutical products, primarily serving healthcare markets in China and other regions where it maintains a commercial presence.

Average Trading Volume: 32,415,442

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$13.25B

See more data about 0460 stock on TipRanks’ Stock Analysis page.